Jokath

Timolol and Travoprost, the active ingredients in Jokath, are a beta‑blocker and a prostaglandin analog presented as an ophthalmic solution for ocular use. It treats primary open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Jokath as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jokath, a combination ocular antihypertensive, is indicated for conditions involving elevated intra‑ocular pressure.

- Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: reduces eye pressure to prevent progression to glaucoma. - Secondary open‑angle glaucoma: helps control pressure when other causes are present.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Conjunctival hyperemia (redness). - Dry eye or foreign‑body sensation. - Transient eyelash growth. - Increased pigmentation of the iris.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Exacerbation of asthma or chronic obstructive pulmonary disease. - Systemic bradycardia or hypotension. - Uveitis or intra‑ocular inflammation. - Corneal ulceration or persistent epithelial defect. - Persistent eyelid edema.

Before prescribing Jokath, clinicians should evaluate cardiovascular and respiratory status and consider patient‑specific factors.

- Cardiovascular assessment: monitor for bradycardia or hypotension. - Respiratory caution: avoid in patients with uncontrolled asthma or severe COPD. - Concomitant beta‑blockers: assess risk of additive systemic effects. - Contact lens wear: advise removal during treatment to reduce irritation. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at room temperature: keep in original container, protect from moisture and light.

Jokath may interact with other systemic or ocular agents; monitoring is advised.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers (e.g., propranolol): risk of additive bradycardia/hypotension. - Calcium channel blockers: may enhance hypotensive effect. - Other prostaglandin analog eye drops: increased risk of ocular side effects.

Moderate Interactions (Monitor Closely): - Topical anesthetic drops: potential corneal toxicity. - Anticholinergic eye drops: may affect pupil response. - Systemic antihypertensives: monitor blood pressure for additive lowering.